Paul Fehlner, Ph.D., J.D., serves as Senior Vice President and Chief Intellectual Property Counsel. He is a scientist-lawyer with more than 30 years’ experience in life sciences, particularly focused on intellectual property matters. Previously he was the Chief Legal Officer and Corporate Secretary, and earlier Chief Intellectual Property Officer, for Axcella Therapeutics, a clinical stage company in Cambridge, Massachusetts. He co-founded reVision Therapeutics, Inc., created to reimagine the drug development lifecycle by repurposing products into high-impact, affordable treatments for ophthalmic diseases. Dr. Fehlner spent nine years as the Global Head of Intellectual Property for Novartis Pharma in Basel, Switzerland. Prior to Novartis, Dr. Fehlner practiced intellectual property law with several firms, reaching the level of partner and life sciences IP practice group leader at Baker Botts LLP, and served as Biotechnology Patent Counsel for Rhône-Poulenc Rorer. Dr. Fehlner assisted the World Health Organization in design of the COVID-19 Technology Access Pool (C-TAP) in 2020-21, presented at the 2019 Brocher Foundation expert working group on access to cell and gene therapies in 2019, and has been named to the IAM Strategy 300 World’s Leading Patent Professionals multiple times. He earned a J.D. from Fordham University School of Law, a Ph.D. in immunology and biochemistry from Rockefeller University (Lois P. Markey Fellow), and a B.S. in chemistry from Haverford College (high honors; Phi Beta Kappa).